MARKET

CRVS

CRVS

Corvus Pharmaceu
NASDAQ
0.8837
+0.0525
+6.32%
After Hours: 0.9250 +0.0413 +4.67% 18:49 10/06 EDT
OPEN
0.8251
PREV CLOSE
0.8312
HIGH
0.8839
LOW
0.8250
VOLUME
145.43K
TURNOVER
0
52 WEEK HIGH
5.50
52 WEEK LOW
0.6950
MARKET CAP
41.14M
P/E (TTM)
-1.1061
1D
5D
1M
3M
1Y
5Y
Corvus Pharma's Partner Secures China Approval For Early-Stage Mupadolimab Trial For Lung, Head & Neck Cancer
Benzinga · 09/27 12:51
Corvus' partner Angel Pharma gets nod to start phase 1/1b trial of cancer therapy in China
Clinical-stage biopharma Corvus Pharmaceuticals (NASDAQ:CRVS</a...
Seekingalpha · 09/26 21:13
Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval For Phase 1/1b Clinical Trial Of Mupadolimab In China
BURLINGAME, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that the IND application to initiate
Benzinga · 09/26 20:13
Corvus Pharmaceuticals Gets China Regulatory Approval for Lung Cancer New Drug Application
Corvus Pharmaceuticals Gets China Regulatory Approval for Lung Cancer New Drug Application
MT Newswires · 09/26 16:30
Great news for Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS): Insiders acquired stock in large numbers last year
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...
Simply Wall St. · 08/26 10:13
Corvus (CRVS) Moves to Buy: Rationale Behind the Upgrade
Corvus (CRVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks · 08/11 16:00
--Cantor Fitzgerald Adjusts Corvus Pharmaceuticals' Price Target to $4 from $8, Keeps Overweight Rating
--Cantor Fitzgerald Adjusts Corvus Pharmaceuticals' Price Target to $4 from $8, Keeps Overweight Rating
MT Newswires · 08/09 12:37
Corvus Pharmaceuticals: Q2 Earnings Insights
  Corvus Pharmaceuticals (NASDAQ:CRVS) reported its Q2 earnings results on Monday, August 8, 2022 at 04:05 PM. Here's what investors need to know about the announcement.
Benzinga · 08/09 03:39
More
About CRVS
Corvus Pharmaceuticals, Inc. is an immunology biopharmaceutical company focused on developing drugs and antibodies that target the critical cellular elements of the immune system. The Company develops drugs and antibodies that target the critical cellular elements of the immune system. The Company's lead product candidate is CPI-006, a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its next product candidate, CPI-818, is a selective, covalent inhibitor of ITK. CPI-818 is designed to inhibit the proliferation of certain malignant T-cells. Its third product candidate, Ciforadenant is an oral, small molecule antagonist of the A2A receptor for adenosine. Its product candidate pipeline includes CPI-006, B-Cell Activating anti-CD73 antibody; CPI-818, ITK Inhibitor, Ciforadenant Adenosine A2A Receptor Antagonist; CPI-182, Anti-CXCR2 Antibody designed to block inflammation and Myeloid Suppression, and CPI-935, Adenosine A2B Receptor Antagonist.

Webull offers kinds of Corvus Pharmaceuticals Inc stock information, including NASDAQ:CRVS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRVS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CRVS stock methods without spending real money on the virtual paper trading platform.